48 completed, 18 terminated, 16 active not recruiting, 7 recruiting. 48 Phase 1, 32 Phase 2, 9 Phase 3, 5 Not applicable, 3 Early Phase 1.
Follow Recurrent Breast Carcinoma: new trials by email Literature Review of Recurrent Breast Carcinoma trials Research Report on Recurrent Breast Carcinoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| 177Lu-DOTATATE for the Treatment of Stage IV or Recurrent Breast Cancer Biopsy, Biospecimen Collection, Computed Tomography - Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma | Phase 2 | Recruiting | OHSU Knight Cancer Institute | 10 | 2026-06-30 | 2026-06-05 |
| Personalized Vaccine Immunotherapy in Combination With Checkpoint Inhibitor for Treatment of Triple Negative Breast Cancer Ipilimumab, Pembrolizumab, Vaccine Therapy - Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8 | Phase 1 | Recruiting | Emory University | 18 | 2025-12-02 | 2026-01-26 |
| Preoperative Partial Breast Reirradiation and Repeat Breast-conserving Surgery in Patients With Recurrent Breast Cancer: the REPEAT Trial ablative single-dose PBI - Recurrent Breast Carcinoma, Ipsilateral Recurrence | Phase 2 | Recruiting | Amsterdam UMC, location VUmc | 25 | 2025-01-01 | 2026-07-16 |
| Study on Recurrent Breast Cancer and Repeated Radiation Therapy Breast conserving surgey and radiotherapy, Mastectomy - Recurrent Breast Carcinoma | Not applicable | Recruiting | Turku University Hospital | 60 | 2024-12-01 | 2026-03-09 |
| SMMART Adaptive Clinical Treatment (ACT) Trial Alectinib, Alpelisib, Anastrozole - Advanced Breast Carcinoma, Advanced Malignant Solid Neoplasm | Early Phase 1 | Withdrawn | OHSU Knight Cancer Institute | 2023-01-30 | 2024-01-23 | |
| Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations Biopsy Procedure, Biospecimen Collection, Computed Tomography - Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8 | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 29 | 2021-04-26 | 2026-08-19 |
| Breast Cancer Vaccine in Combination With Pembrolizumab for Treatment of Persistent, Recurrent, or Metastatic Breast Cancer Cyclophosphamide, Allogeneic GM-CSF-secreting Breast Cancer Vaccine SV-BR-1-GM, Pembrolizumab - Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma | Phase 1 / Phase 2 | Withdrawn | Thomas Jefferson University | 2020-12-21 | 2025-04-29 | |
| Testing the Addition of an Anti-cancer Drug, Berzosertib, to the Usual Treatment (Radiation Therapy) for Chemotherapy-Resistant Triple-Negative and Estrogen and/or Progesterone Receptor Positive, HER2 Negative Breast Cancer Berzosertib, Biospecimen Collection, Quality-of-Life Assessment - Bilateral Breast Carcinoma, HER2-Negative Breast Carcinoma | Phase 1 | Active not recruiting | National Cancer Institute (NCI) | 42 | 2020-09-24 | 2026-07-31 |
| A Vaccine (MV-s-NAP) for the Treatment of Patients With Invasive Metastatic Breast Cancer Oncolytic Measles Virus Encoding Helicobacter pylori Neutrophil-activating Protein, Computed Tomography, Magnetic Resonance Imaging - Anatomic Stage IV Breast Cancer AJCC v8, Invasive Breast Carcinoma | Phase 1 | Recruiting | Mayo Clinic | 54 | 2020-09-23 | 2026-07-31 |
| Testing the Addition of Copanlisib to Usual Treatment (Fulvestrant and Abemaciclib) in Metastatic Breast Cancer Abemaciclib, Biopsy Procedure, Biospecimen Collection - Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma | Phase 1 | Active not recruiting | National Cancer Institute (NCI) | 24 | 2020-06-17 | 2026-09-08 |
| T-VEC With Chemotherapy or Endocrine Therapy in Treating Participants With HER2- Negative Breast Cancer Anastrozole, Exemestane, Fulvestrant - Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8 | Phase 1 | Completed | University of California, San Francisco | 20 | 2020-02-05 | 2025-05-21 |
| Paclitaxel Therapeutic Drug Monitoring in Cancer Patients Blood draws, QLQ-CIPN20 Survey, PR-CTCAE Survey - Solid Tumor, Adult, Metastatic Nonsmall Cell Lung Cancer | Suspended | Wake Forest University Health Sciences | 55 | 2019-11-11 | 2026-08-13 | |
| Clinical Information and Biospecimen Collection From Patients With Recurrent or Stage IV Breast Cancer Biospecimen Collection, Medical Chart Review - Anatomic Stage IV Breast Cancer AJCC v8, Invasive Breast Carcinoma | Active not recruiting | Mayo Clinic | 300 | 2019-09-16 | 2026-06-04 | |
| Estradiol in Treating Patients With ER Beta Positive, Triple Negative Locally Advanced or Metastatic Breast Cancer Biopsy, Computed Tomography, Magnetic Resonance Imaging - Advanced Triple-Negative Breast Carcinoma, Anatomic Stage III Breast Cancer AJCC v8 | Phase 2 | Active not recruiting | Mayo Clinic | 8 | 2019-08-28 | 2026-05-12 |
| Effect of PACK Health Support Program on Patient Reported Outcomes in Patients With Breast Cancer Best Practice, Medical Chart Review, Quality-of-Life Assessment - Breast Carcinoma, Breast Ductal Carcinoma In Situ | Not applicable | Completed | M.D. Anderson Cancer Center | 287 | 2019-07-31 | 2023-08-07 |
| Avelumab With Binimetinib, Sacituzumab Govitecan, or Liposomal Doxorubicin in Treating Stage IV or Unresectable, Recurrent Triple Negative Breast Cancer Anti-OX40 Antibody PF-04518600, Avelumab, Binimetinib - Stage III Breast Cancer, Stage IIIA Breast Cancer | Phase 2 | Active not recruiting | Laura Huppert, MD, BA | 145 | 2019-07-08 | 2026-04-17 |
| Alpelisib and Enzalutamide in Treating Patients With Androgen Receptor and PTEN Positive Metastatic Breast Cancer Alpelisib, Enzalutamide - Advanced Breast Carcinoma, Anatomic Stage III Breast Cancer AJCC v8 | Phase 1 | Completed | M.D. Anderson Cancer Center | 18 | 2019-06-07 | 2024-10-10 |
| Hyperthermia and Olaparib in Treating Breast Cancer Patients With Chest Wall Recurrences Olaparib, Hyperthermia Treatment, Questionnaire Administration - Metastatic Malignant Neoplasm in the Chest Wall, Recurrent Breast Carcinoma | Phase 1 | Terminated | Thomas Jefferson University | 3 | 2019-05-20 | 2025-12-22 |
| Effect of Pembrolizumab and Cisplatin on Metastatic, Locally Recurrent or Inoperable Triple-Negative Breast Cancer Pembrolizumab, Cisplatin - Estrogen Receptor Negative, HER2/Neu Negative | Phase 2 | Withdrawn | University of Washington | 2019-04-01 | 2019-04-26 | |
| Breast Cancer Pathways Program Impact on Patient Shared Decision Making and Experience in Academic and Community Practice Informational Intervention, Quality-of-Life Assessment, Survey Administration - Anatomic Stage IV Breast Cancer AJCC v8, Breast Carcinoma | Not applicable | Completed | Roswell Park Cancer Institute | 174 | 2019-02-06 | 2023-04-10 |
Showing 20 of 95. Sign in to see all of them.
Breast Neoplasms (95) · Triple Negative Breast Neoplasms (24) · Ovarian Neoplasms (13) · Breast Neoplasms, Male (12) · Prostatic Neoplasms (8) · Pancreatic Neoplasms (7) · Brain Neoplasms (6) · Carcinoma, Renal Cell (6) · Fallopian Tube Neoplasms (6) · Melanoma (6) · Neoplasm Metastasis (6) · Carcinoma, Non-Small-Cell Lung (5) · Colorectal Neoplasms (4) · Lung Neoplasms (4) · Sarcoma (4)
Breast Diseases (95) · Neoplasms by Site (95) · Skin Diseases (95) · Skin and Connective Tissue Diseases (95) · Neoplasms (94) · Urogenital Diseases (17) · Urogenital Neoplasms (17) · Endocrine System Diseases (16) · Female Urogenital Diseases (16) · Female Urogenital Diseases and Pregnancy Complications (16) · Endocrine Gland Neoplasms (15) · Genital Diseases (15) · Adnexal Diseases (13) · Genital Diseases, Female (13) · Genital Neoplasms, Female (13)
Paclitaxel (12) · Specimen Handling (10) · Taxes (10) · Trastuzumab (10) · Magnetic Resonance Spectroscopy (9) · PF-05280014 (9) · Biopsy (8) · Immunoglobulin G (7) · Bevacizumab (6) · Carboplatin (6) · Cyclophosphamide (6) · Disulfides (6) · Fulvestrant (6) · Lapatinib (6) · Ogivri (6)
National Cancer Institute (NCI) (44) · Mayo Clinic (11) · M.D. Anderson Cancer Center (7) · University of Washington (6) · Northwestern University (4) · City of Hope Medical Center (2) · OHSU Knight Cancer Institute (2) · Roswell Park Cancer Institute (2) · Thomas Jefferson University (2) · Amsterdam UMC, location VUmc (1) · ETOP IBCSG Partners Foundation (1) · Emory University (1) · George W. Sledge Jr. (1) · Laura Huppert, MD, BA (1) · Montefiore Medical Center (1)
United States (90) · Canada (6) · Puerto Rico (6) · South Korea (2) · Switzerland (2) · Finland (1) · Guam (1) · Ireland (1) · Netherlands (1) · Saudi Arabia (1) · South Africa (1)
Cynthia Ma (3) · Funda Meric-Bernstam (2) · Hannah Linden (2) · Hope S Rugo (2) · Matthew P Goetz (2) · Naoto T Ueno (2) · Patricia LoRusso (2) · Roisin M Connolly (2) · Shannon Puhalla (2) · A P Chen (1) · Amy J Chien, MD (1) · Antoinette Tan (1) · Banu Arun (1) · Bhavana Pothuri (1) · Bhuvaneswari Ramaswamy, MD (1)
PMID 34616010, PMID 24095609, PMID 24583822, PMID 24881463, PMID 25348000, PMID 25495490, PMID 25947565, PMID 26056183, PMID 26092816, PMID 26123926, PMID 26586415, PMID 27022111, PMID 27044936, PMID 27138575, PMID 28620884, PMID 28911092, PMID 29789969, PMID 29863451, PMID 31276981, PMID 31277699, PMID 31618131, PMID 31821109, PMID 32060053, PMID 32379297, PMID 32463741, PMID 33048619, PMID 33115815, PMID 33852121, PMID 33885704, PMID 34357781, PMID 35133871, PMID 35138919, PMID 36092362, PMID 36351402, PMID 36493334, PMID 36521078, PMID 36623515, PMID 36943254, PMID 37053535, PMID 37311055, PMID 37322121, PMID 37506981, PMID 37823909, PMID 37934000, PMID 38591867, PMID 38967884, PMID 39169033, PMID 39666929, PMID 39693587, PMID 39863139
P30CA016672 (8), P30CA015083 (7), U10CA180821 (6), N01CM00099 (4), P30CA060553 (4), U01CA062461 (4), U01CA062490 (4), P30CA013330 (3), P30CA015704 (3), P30CA022453 (3), U01CA062487 (3), U01CA069912 (3), U01CA070095 (3), U01CA099168 (3), U10CA031946 (3)